Elegen and Nutcracker Therapeutics launched a pilot program to demonstrate what they label the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer ...
It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...
LONDON--(BUSINESS WIRE)--Mytos, an innovative leader in automated cell manufacturing, announced today it has closed $19M in Series A financing led by Buckley Ventures, with participation from IQ ...
With the power of robotics and the personalized medicine expertise of one of Japan's top drugmakers, Astellas Pharma and Yaskawa Electric Corporation are setting off on a joint venture to help ...
Collaboration with Stanford Medicine establishes a platform manufacturing process and analytics designed to support gene-edited hematopoietic stem cell therapies for HIV and more than 19 rare diseases ...
In this innovation spotlight, Tia Harmon, technical science liaison, CGT for PHC Corporation of North America (PHCNA), discusses the key challenges in CGT manufacturing and how in-line monitoring ...
Fully cell-free process aims to further democratize personalized cancer therapeutic manufacturing with shorter turnaround times and negligible bioburden and endotoxin risks. As late-stage PCT clinical ...
Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results